25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aryx Therapeutics I
Buy, Hold or Sell?

Let's analyze Aryx together

I guess you are interested in Aryx Therapeutics I. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aryx Therapeutics I. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aryx Therapeutics I

I send you an email if I find something interesting about Aryx Therapeutics I.

1. Quick Overview

1.1. Quick analysis of Aryx (30 sec.)










1.2. What can you expect buying and holding a share of Aryx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.09
Expected worth in 1 year
$-3.71
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-3.63
Return On Investment
-725,144.9%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0 - $0.0005
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aryx (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-19.03 - $-22.65
Total Value Per Share
$-19.11 - $-22.73

2.2. Growth of Aryx (5 min.)




Is Aryx growing?

Current yearPrevious yearGrowGrow %
How rich?-$2.9m$27.4m-$30.3m-1,040.2%

How much money is Aryx making?

Current yearPrevious yearGrowGrow %
Making money-$33.1m-$31.2m-$1.9m-5.9%
Net Profit Margin0.0%-158.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Aryx (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aryx?

Welcome investor! Aryx's management wants to use your money to grow the business. In return you get a share of Aryx.

First you should know what it really means to hold a share of Aryx. And how you can make/lose money.

Speculation

The Price per Share of Aryx is $0.0005. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aryx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aryx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.09. Based on the TTM, the Book Value Change Per Share is $-0.91 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aryx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.99-198,236.8%-0.99-198,236.8%-0.93-186,587.8%-0.88-176,006.2%-0.88-176,006.2%
Usd Book Value Change Per Share-0.91-181,286.2%-0.91-181,286.2%-0.24-47,409.0%-0.02-3,485.7%-0.02-3,485.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.91-181,286.2%-0.91-181,286.2%-0.24-47,409.0%-0.02-3,485.7%-0.02-3,485.7%
Usd Price Per Share3.21-3.21-2.90-2.77-2.77-
Price to Earnings Ratio-3.24--3.24--3.11--3.15--3.15-
Price-to-Total Gains Ratio-3.54--3.54--12.23--4.59--4.59-
Price to Book Ratio-36.84--36.84-3.54--5.19--5.19-
Price-to-Total Gains Ratio-3.54--3.54--12.23--4.59--4.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0005
Number of shares2000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.91-0.02
Usd Total Gains Per Share-0.91-0.02
Gains per Quarter (2000000 shares)-1,812,862.35-34,857.45
Gains per Year (2000000 shares)-7,251,449.41-139,429.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-7251449-72514590-139430-139440
20-14502899-145029080-278860-278870
30-21754348-217543570-418289-418300
40-29005798-290058060-557719-557730
50-36257247-362572550-697149-697160
60-43508696-435087040-836579-836590
70-50760146-507601530-976009-976020
80-58011595-580116020-1115438-1115450
90-65263045-652630510-1254868-1254880
100-72514494-725145000-1394298-1394310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.05.00.00.0%0.05.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.04.00.020.0%1.04.00.020.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.05.00.0%0.00.05.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.04.00.020.0%1.04.00.020.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aryx Therapeutics I compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.906-0.9060%-0.237-74%-0.017-98%-0.017-98%
Book Value Per Share---0.087-0.0870%0.819-111%-0.603+592%-0.603+592%
Current Ratio--1.0151.0150%4.161-76%3.607-72%3.607-72%
Debt To Asset Ratio--1.2351.2350%0.464+166%1.571-21%1.571-21%
Debt To Equity Ratio----0%0.866-100%0.367-100%0.367-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.991-0.9910%-0.933-6%-0.880-11%-0.880-11%
Free Cash Flow Per Share---1.049-1.0490%-1.371+31%-0.841-20%-0.841-20%
Free Cash Flow To Equity Per Share---1.110-1.1100%-0.529-52%-0.199-82%-0.199-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---22.647--------
Intrinsic Value_10Y_min---19.026--------
Intrinsic Value_1Y_max---1.345--------
Intrinsic Value_1Y_min---1.307--------
Intrinsic Value_3Y_max---4.746--------
Intrinsic Value_3Y_min---4.470--------
Intrinsic Value_5Y_max---8.997--------
Intrinsic Value_5Y_min---8.203--------
Market Cap16731.000-641900%107413020.000107413020.0000%97039800.000+11%92756664.000+16%92756664.000+16%
Net Profit Margin----0%-1.5830%-2.7960%-2.7960%
Operating Margin----0%-1.5610%-2.8910%-2.8910%
Operating Ratio----0%2.542-100%3.488-100%3.488-100%
Pb Ratio-0.006+100%-36.836-36.8360%3.540-1141%-5.192-86%-5.192-86%
Pe Ratio-0.001+100%-3.239-3.2390%-3.108-4%-3.151-3%-3.151-3%
Price Per Share0.001-641900%3.2103.2100%2.900+11%2.772+16%2.772+16%
Price To Free Cash Flow Ratio0.000+100%-3.060-3.0600%-2.116-31%-2.874-6%-2.874-6%
Price To Total Gains Ratio-0.001+100%-3.541-3.5410%-12.234+245%-4.589+30%-4.589+30%
Quick Ratio--0.9350.9350%4.826-81%4.665-80%4.665-80%
Return On Assets---2.673-2.6730%-0.610-77%-1.000-63%-1.000-63%
Return On Equity----0%-1.1390%-0.3840%-0.3840%
Total Gains Per Share---0.906-0.9060%-0.237-74%-0.017-98%-0.017-98%
Usd Book Value---2916000.000-2916000.0000%27415000.000-111%-20190800.000+592%-20190800.000+592%
Usd Book Value Change Per Share---0.906-0.9060%-0.237-74%-0.017-98%-0.017-98%
Usd Book Value Per Share---0.087-0.0870%0.819-111%-0.603+592%-0.603+592%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.991-0.9910%-0.933-6%-0.880-11%-0.880-11%
Usd Free Cash Flow---35108000.000-35108000.0000%-45862000.000+31%-28125800.000-20%-28125800.000-20%
Usd Free Cash Flow Per Share---1.049-1.0490%-1.371+31%-0.841-20%-0.841-20%
Usd Free Cash Flow To Equity Per Share---1.110-1.1100%-0.529-52%-0.199-82%-0.199-82%
Usd Market Cap16731.000-641900%107413020.000107413020.0000%97039800.000+11%92756664.000+16%92756664.000+16%
Usd Price Per Share0.001-641900%3.2103.2100%2.900+11%2.772+16%2.772+16%
Usd Profit---33167000.000-33167000.0000%-31218000.000-6%-29447600.000-11%-29447600.000-11%
Usd Revenue----0%19724000.000-100%5724200.000-100%5724200.000-100%
Usd Total Gains Per Share---0.906-0.9060%-0.237-74%-0.017-98%-0.017-98%
 EOD+2 -6MRQTTM+0 -0YOY+12 -185Y+13 -1710Y+13 -17

3.3 Fundamental Score

Let's check the fundamental score of Aryx Therapeutics I based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.001
Price to Book Ratio (EOD)Between0-1-0.006
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.935
Current Ratio (MRQ)Greater than11.015
Debt to Asset Ratio (MRQ)Less than11.235
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.673
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Aryx Therapeutics I based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Aryx Therapeutics I

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.

Fundamental data was last updated by Penke on 2024-11-22 12:50:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aryx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aryx Therapeutics I:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-158.3%+158.3%
TTM-5Y-279.6%+279.6%
5Y-279.6%10Y-279.6%0.0%
4.3.1.2. Return on Assets

Shows how efficient Aryx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • -267.3% Return on Assets means that Aryx generated $-2.67 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aryx Therapeutics I:

  • The MRQ is -267.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -267.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-267.3%TTM-267.3%0.0%
TTM-267.3%YOY-61.0%-206.3%
TTM-267.3%5Y-100.0%-167.3%
5Y-100.0%10Y-100.0%0.0%
4.3.1.3. Return on Equity

Shows how efficient Aryx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Aryx generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aryx Therapeutics I:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-113.9%+113.9%
TTM-5Y-38.4%+38.4%
5Y-38.4%10Y-38.4%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aryx Therapeutics I.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aryx is operating .

  • Measures how much profit Aryx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aryx Therapeutics I:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-156.1%+156.1%
TTM-5Y-289.1%+289.1%
5Y-289.1%10Y-289.1%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Aryx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aryx Therapeutics I:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.542-2.542
TTM-5Y3.488-3.488
5Y3.48810Y3.4880.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aryx Therapeutics I.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aryx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.01 means the company has $1.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aryx Therapeutics I:

  • The MRQ is 1.015. The company is just able to pay all its short-term debts.
  • The TTM is 1.015. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.015TTM1.0150.000
TTM1.015YOY4.161-3.146
TTM1.0155Y3.607-2.593
5Y3.60710Y3.6070.000
4.4.3.2. Quick Ratio

Measures if Aryx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.93 means the company can pay off $0.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aryx Therapeutics I:

  • The MRQ is 0.935. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.935. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.935TTM0.9350.000
TTM0.935YOY4.826-3.891
TTM0.9355Y4.665-3.730
5Y4.66510Y4.6650.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aryx Therapeutics I.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aryx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aryx to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.24 means that Aryx assets are financed with 123.5% credit (debt) and the remaining percentage (100% - 123.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aryx Therapeutics I:

  • The MRQ is 1.235. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.235. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.235TTM1.2350.000
TTM1.235YOY0.464+0.771
TTM1.2355Y1.571-0.336
5Y1.57110Y1.5710.000
4.5.4.2. Debt to Equity Ratio

Measures if Aryx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aryx Therapeutics I:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.866-0.866
TTM-5Y0.367-0.367
5Y0.36710Y0.3670.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aryx generates.

  • Above 15 is considered overpriced but always compare Aryx to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.24 means the investor is paying $-3.24 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aryx Therapeutics I:

  • The EOD is -0.001. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.239. Based on the earnings, the company is expensive. -2
  • The TTM is -3.239. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.001MRQ-3.239+3.238
MRQ-3.239TTM-3.2390.000
TTM-3.239YOY-3.108-0.130
TTM-3.2395Y-3.151-0.087
5Y-3.15110Y-3.1510.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aryx Therapeutics I:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.060. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.060. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-3.060+3.059
MRQ-3.060TTM-3.0600.000
TTM-3.060YOY-2.116-0.944
TTM-3.0605Y-2.874-0.185
5Y-2.87410Y-2.8740.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aryx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -36.84 means the investor is paying $-36.84 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aryx Therapeutics I:

  • The EOD is -0.006. Based on the equity, the company is expensive. -2
  • The MRQ is -36.836. Based on the equity, the company is expensive. -2
  • The TTM is -36.836. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.006MRQ-36.836+36.830
MRQ-36.836TTM-36.8360.000
TTM-36.836YOY3.540-40.375
TTM-36.8365Y-5.192-31.644
5Y-5.19210Y-5.1920.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2005-12-312006-12-312007-12-312008-12-312009-12-31
Current Deferred Revenue 4,493-5973,896173,9139154,828-5,513-685
Net Debt  -1,290-7,494-8,784-39,712-48,49627,179-21,31725,6034,286



6.2. Latest Balance Sheet

Balance Sheet of 2009-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets12,406
Total Liabilities15,322
Total Stockholder Equity-2,916
 As reported
Total Liabilities 15,322
Total Stockholder Equity+ -2,916
Total Assets = 12,406

Assets

Total Assets12,406
Total Current Assets8,807
Long-term Assets3,599
Total Current Assets
Cash And Cash Equivalents 7,409
Short-term Investments 353
Other Current Assets 895
Total Current Assets  (as reported)8,807
Total Current Assets  (calculated)8,657
+/- 150
Long-term Assets
Property Plant Equipment 2,258
Other Assets 1,341
Long-term Assets  (as reported)3,599
Long-term Assets  (calculated)3,599
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,681
Long-term Liabilities6,641
Total Stockholder Equity-2,916
Total Current Liabilities
Short-term Debt 5,183
Short Long Term Debt 4,850
Accounts payable 685
Other Current Liabilities 2,813
Total Current Liabilities  (as reported)8,681
Total Current Liabilities  (calculated)13,531
+/- 4,850
Long-term Liabilities
Long term Debt 5,283
Other Liabilities 1,358
Long-term Liabilities  (as reported)6,641
Long-term Liabilities  (calculated)6,641
+/-0
Total Stockholder Equity
Common Stock28
Retained Earnings -187,109
Other Stockholders Equity 184,165
Total Stockholder Equity (as reported)-2,916
Total Stockholder Equity (calculated)-2,916
+/-0
Other
Cash and Short Term Investments 7,762
Common Stock Shares Outstanding 27,438
Current Deferred Revenue-685
Liabilities and Stockholders Equity 12,406
Net Debt 4,286
Net Tangible Assets -2,916
Net Working Capital 126
Short Long Term Debt Total 11,695



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
8,847
0
33,312
56,764
69,625
51,148
12,406
12,40651,14869,62556,76433,31208,847
   > Total Current Assets 
0
0
27,716
51,411
64,899
45,850
8,807
8,80745,85064,89951,41127,71600
       Cash And Cash Equivalents 
0
0
12,455
18,660
55,476
35,999
7,409
7,40935,99955,47618,66012,45500
       Short-term Investments 
0
0
13,886
31,648
7,640
8,588
353
3538,5887,64031,64813,88600
       Net Receivables 
0
0
0
45
0
0
0
00045000
       Other Current Assets 
0
0
1,375
1,058
1,633
381
895
8953811,6331,0581,37500
   > Long-term Assets 
0
0
5,596
5,353
4,726
5,298
3,599
3,5995,2984,7265,3535,59600
       Property Plant Equipment 
0
0
4,143
4,169
3,655
3,198
2,258
2,2583,1983,6554,1694,14300
       Other Assets 
0
0
1,453
1,184
1,071
2,100
1,341
1,3412,1001,0711,1841,45300
> Total Liabilities 
0
0
100,400
150,476
34,278
23,733
15,322
15,32223,73334,278150,476100,40000
   > Total Current Liabilities 
0
0
7,746
11,527
13,457
11,019
8,681
8,68111,01913,45711,5277,74600
       Short-term Debt 
0
0
2,244
3,197
3,536
3,737
5,183
5,1833,7373,5363,1972,24400
       Short Long Term Debt 
0
0
0
3,197
3,536
3,404
4,850
4,8503,4043,5363,197000
       Accounts payable 
0
0
656
691
1,369
2,454
685
6852,4541,36969165600
       Other Current Liabilities 
0
0
4,846
3,743
4,639
4,828
2,813
2,8134,8284,6393,7434,84600
   > Long-term Liabilities 
0
0
92,654
138,949
20,821
12,714
6,641
6,64112,71420,821138,94992,65400
       Other Liabilities 
0
0
2,378
21,605
17,377
2,555
1,358
1,3582,55517,37721,6052,37800
> Total Stockholder Equity
-18,874
0
-67,088
-93,712
35,347
27,415
-2,916
-2,91627,41535,347-93,712-67,0880-18,874
   Retained Earnings -187,109-153,942-122,724-95,163-67,83500
   Accumulated Other Comprehensive Income 
0
0
-298
0
0
45
0
04500-29800
   Capital Surplus 0000000
   Treasury Stock0000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2009-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-31,238
Operating Income-31,238-31,238
 
Operating Expense (+$)
Research Development21,040
Selling General Administrative10,198
Selling And Marketing Expenses0
Operating Expense31,23831,238
 
Net Interest Income (+$)
Interest Income0
Interest Expense-2,007
Other Finance Cost-2,007
Net Interest Income0
 
Pretax Income (+$)
Operating Income-31,238
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-33,167-29,309
EBIT - interestExpense = -33,245
-32,318
-31,160
Interest Expense2,007
Earnings Before Interest and Taxes (EBIT)-31,238-31,160
Earnings Before Interest and Taxes (EBITDA)-30,158
 
After tax Income (+$)
Income Before Tax-33,167
Tax Provision-0
Net Income From Continuing Ops-33,167-33,167
Net Income-33,167
Net Income Applicable To Common Shares-33,167
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses31,238
Total Other Income/Expenses Net-1,9290
 

Technical Analysis of Aryx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aryx. The general trend of Aryx is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aryx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aryx Therapeutics I.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.0005 < 0.0005 < 0.0005.

The bearish price targets are: .

Tweet this
Aryx Therapeutics I Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aryx Therapeutics I. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aryx Therapeutics I Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aryx Therapeutics I. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aryx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aryx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aryx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aryx Therapeutics I Daily Moving Average Convergence/Divergence (MACD) ChartAryx Therapeutics I Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aryx Therapeutics I. The current adx is 7.14285714.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aryx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Aryx Therapeutics I Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aryx Therapeutics I. The current sar is 0.0005.

Aryx Therapeutics I Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aryx Therapeutics I. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Aryx Therapeutics I Daily Relative Strength Index (RSI) ChartAryx Therapeutics I Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aryx Therapeutics I. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aryx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aryx Therapeutics I Daily Stochastic Oscillator ChartAryx Therapeutics I Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aryx Therapeutics I. The current cci is -666.66666667.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Aryx Therapeutics I Daily Commodity Channel Index (CCI) ChartAryx Therapeutics I Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aryx Therapeutics I. The current cmo is 0.

Aryx Therapeutics I Daily Chande Momentum Oscillator (CMO) ChartAryx Therapeutics I Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aryx Therapeutics I. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aryx Therapeutics I Daily Williams %R ChartAryx Therapeutics I Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aryx Therapeutics I.

Aryx Therapeutics I Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aryx Therapeutics I. The current atr is 0.000036.

Aryx Therapeutics I Daily Average True Range (ATR) ChartAryx Therapeutics I Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aryx Therapeutics I. The current obv is 0.

Aryx Therapeutics I Daily On-Balance Volume (OBV) ChartAryx Therapeutics I Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aryx Therapeutics I. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aryx Therapeutics I Daily Money Flow Index (MFI) ChartAryx Therapeutics I Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aryx Therapeutics I.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Aryx Therapeutics I Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aryx Therapeutics I based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aryx with someone you think should read this too:
  • Are you bullish or bearish on Aryx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aryx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aryx Therapeutics I

I send you an email if I find something interesting about Aryx Therapeutics I.


Comments

How you think about this?

Leave a comment

Stay informed about Aryx Therapeutics I.

Receive notifications about Aryx Therapeutics I in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.